Level Biotechnology Profit Margin

The latest profit margin for 3118.TWO is 10.72% as of June 2026. That compares with 9.37% in the prior-year period — up 14.4% year over year. That is above the Healthcare sector average of 10.58%. Investors often review this figure alongside Level Biotechnology's historical trend and sector peers before judging valuation or financial health.

Over the past year, 3118.TWO's profit margin moved from 9.37% to 10.72% — a 14.4% year-over-year increase. If the trend continues in the same direction for several quarters, it can signal a meaningful shift in Level Biotechnology's valuation or profitability profile.

Against Healthcare companies, 3118.TWO currently prints 10.72% for profit margin, while the sector average sits near 10.58%. That is roughly 1.3% above the sector mean. Large gaps often invite a closer look at Level Biotechnology's growth, margins, and balance sheet.

Profit Margin shows how effectively Level Biotechnology converts resources into returns. At 10.72%, 3118.TWO may look efficient or underperforming depending on peer benchmarks and trend direction. That compares with 9.37% in the prior-year period — up 14.4% year over year. Pair the percentage with revenue growth and leverage for a fuller health check.

After noting 3118.TWO's profit margin (10.72%), review year-over-year change from 9.37%, peer averages, and a few neighboring metrics such as revenue, margins, or valuation multiples. That combination usually beats staring at a single figure. The navigation links on this page jump you to those related views.